Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.58

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned a consensus recommendation of “Hold” from the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. Thirteen analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $19.5833.

A number of brokerages have recently commented on KVUE. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Finally, UBS Group upped their price objective on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th.

Kenvue Stock Performance

Shares of KVUE opened at $17.43 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The firm’s 50 day moving average is $17.97 and its 200-day moving average is $17.17. Kenvue has a 12-month low of $14.02 and a 12-month high of $25.17. The stock has a market capitalization of $33.40 billion, a P/E ratio of 22.63, a P/E/G ratio of 3.95 and a beta of 0.51.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.26 earnings per share. Equities research analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 107.79%.

Institutional Trading of Kenvue

Several large investors have recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. increased its holdings in shares of Kenvue by 15.3% in the 2nd quarter. Avantax Advisory Services Inc. now owns 213,735 shares of the company’s stock valued at $4,473,000 after purchasing an additional 28,414 shares during the period. Rockefeller Capital Management L.P. grew its position in Kenvue by 151.3% during the second quarter. Rockefeller Capital Management L.P. now owns 475,778 shares of the company’s stock valued at $9,958,000 after purchasing an additional 286,435 shares in the last quarter. Western Wealth Management LLC grew its position in Kenvue by 10.8% during the second quarter. Western Wealth Management LLC now owns 12,636 shares of the company’s stock valued at $264,000 after purchasing an additional 1,236 shares in the last quarter. Frank Rimerman Advisors LLC increased its stake in Kenvue by 24.2% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 23,027 shares of the company’s stock valued at $482,000 after buying an additional 4,494 shares during the period. Finally, Vanguard Group Inc. lifted its position in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after buying an additional 4,101,880 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.